Balsalazide

Balsalazide sodium is a pro-drug of 5-aminosalicylic acid (5-ASA). It acts as a carrier to deliver 5-ASA to the colonic site of action. 5-ASA exerts local anti-inflammatory effects in the bowel.

Adult

Treatment of mild to moderate ulcerative colitis, acute attack: 2.25 g 3 times a day until remission occurs or for up to a maximum of 12 weeks. Maintenance of remission of ulcerative colitis: 1.5 g twice daily, adjusted according to response.

Renal adjustment

Avoid in moderate to severe impairment. Renal function should be monitored more frequently.

Hepatic adjustment

Caution; avoid in severe impairment (no information available).

Max dose

6.75 g per day

• Salicylate hypersensitivity
• Severe hepatic impairment
• Moderate to severe renal impairment
• History of asthma